Libero Santarpia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/850404/publications.pdf

Version: 2024-02-01

66 papers	5,114 citations	109137 35 h-index	123241 61 g-index
66 all docs	66 docs citations	66 times ranked	9905 citing authors

#	Article	IF	Citations
1	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of Thoracic Oncology, 2022, 17, 103-115.	0.5	89
2	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal of Cancer, 2018, 118, 1107-1114.	2.9	26
3	Progress in nonviral gene therapy for breast cancer and what comes next?. Expert Opinion on Biological Therapy, 2017, 17, 595-611.	1.4	32
4	Integrated MicroRNAâ€“mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 194.	1.8	18
5	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	1.2	9
6	Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental and Clinical Cancer Research, 2016, 35, 103.	3.5	160
7	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist, 2016, 21, 1063-1078.	1.9	41
8	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer, 2016, 138, 87-97.	2.3	136
9	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. Npj Breast Cancer, 2016, 2, 16033.	2.3	41
10	miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research and Treatment, 2016, 160, 439-446.	1.1	678
11	Circulating Nucleic Acids (RNA/DNA) in Breast Cancer. , 2016, , 235-256.		0
12	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research, 2015, 21, 1207-1214.	3.2	191
13	Notch is a direct negative regulator of the DNA-damage response. Nature Structural and Molecular Biology, 2015, 22, 417-424.	3.6	68
14	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	0.8	135
15	TP53 mutationâ€correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53â€mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	2.1	59
16	Prolylâ€isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Molecular Medicine, 2014, 6, 99-119.	3.3	130
17	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opinion on Biological Therapy, 2014, 14, 1667-1683.	1.4	36
18	miRNAs in medullary thyroid carcinoma: when will they be relevant to the clinic?. International Journal of Endocrine Oncology, 2014, 1, 7-10.	0.4	0

#	Article	IF	Citations
19	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	3.4	106
20	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 377-389.	12.5	164
21	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist, 2013, 18, 1063-1073.	1.9	75
22	A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 809-823.	1.6	74
23	Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma. International Journal of Endocrinology, 2013, 2013, 1-16.	0.6	34
24	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	1.3	109
25	Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. Current Pharmaceutical Design, 2013, 19, 864-882.	0.9	5
26	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Research, 2013, 15, R86.	2.2	44
27	Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers. Current Pharmaceutical Design, 2013, 19, 864-82.	0.9	3
28	E16. Clinical implications of microRNAs in breast cancer. European Journal of Cancer, 2012, 48, S32-S34.	1.3	0
29	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine, 2012, 59, 218-222.	1.4	26
30	Targeting the MAPKâ€“RASâ€“RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 103-119.	1.5	740
31	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
32	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	2.0	265
33	RET TKI: Potential Role in Thyroid Cancers. Current Oncology Reports, 2012, 14, 97-104.	1.8	38
34	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast, 2012, 21, 336-342.	0.9	12
35	Predictive molecular markers of anthracycline effectiveness in early breast cancer. European Journal of Cancer, Supplement, 2011, 9, 16-21.	2.2	1
36	Uncovering the metabolomic fingerprint of breast cancer. International Journal of Biochemistry and Cell Biology, 2011, 43, 1010-1020.	1.2	77

#	Article	IF	Citations
37	Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. European Journal of Cancer, 2011, 47, S370-S372.	1.3	11
38	Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast, 2011, 20, S135-S141.	0.9	14
39	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. Current Breast Cancer Reports, 2011, 3, 24-33.	0.5	0
40	Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. Journal of Medical Case Reports, 2011, 5, 301.	0.4	5
41	Inhibition of pituitary tumorâ€transforming geneâ€1 in thyroid cancer cells by drugs that decrease specificity proteins. Molecular Carcinogenesis, 2011, 50, 655-667.	1.3	35
42	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. Future Oncology, 2011, 7, 173-186.	1.1	4
43	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	3.0	203
44	Genetic alterations in the RAS/RAF/mitogenâ€activated protein kinase and phosphatidylinositol 3â€kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer, 2010, 116, 2974-2983.	2.0	70
45	Lymphocytic Hypophysitis: Differential Diagnosis and Effects of High-Dose Pulse Steroids, Followed by Azathioprine, on the Pituitary Mass and Endocrine Abnormalities â€" Report of a Case and Literature Review. Scientific World Journal, The, 2010, 10, 126-134.	0.8	24
46	The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors. Endocrine Reviews, 2010, 31, 578-599.	8.9	56
47	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Related Cancer, 2010, 17, F51-F75.	1.6	53
48	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.4	58
49	Breast cancer assessment tools and optimizing adjuvant therapy. Nature Reviews Clinical Oncology, 2010, 7, 725-732.	12.5	83
50	Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm. Endocrine Practice, 2009, 15, 597-604.	1.1	7
51	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 386-391.	1.8	120
52	Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head and Neck, 2009, 31, 419-423.	0.9	23
53	The role of topoisomerase IIÎ± and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treatment Reviews, 2009, 35, 662-667.	3.4	30
54	Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Human Pathology, 2009, 40, 827-833.	1.1	28

#	Article	IF	Citations
55	Erratum to â€œDetection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinomaâ€•[Hum Pathol 40 (2009) 827-833]. Human Pathology, 2009, 40, 1212.	1.1	0
56	Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology, 2008, 39, 15-20.	1.1	37
57	PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Cancer Investigation, 2008, 26, 1044-1051.	0.6	11
58	A Novel Von Hippelâ€“Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. Cancer Investigation, 2008, 26, 642-646.	0.6	2
59	Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 278-284.	1.8	177
60	High Resolution Array-Comparative Genomic Hybridization Profiling Reveals Deoxyribonucleic Acid Copy Number Alterations Associated with Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4367-4372.	1.8	39
61	Four Patients with Cutaneous Metastases from Medullary Thyroid Cancer. Thyroid, 2008, 18, 901-905.	2.4	20
62	Mosaicism in von Hippelâ€Lindau disease: an event important to recognize. Journal of Cellular and Molecular Medicine, 2007, 11, 1408-1415.	1.6	22
63	Missense Mutation in the Transcription Factor NKX2â€“5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1428-1433.	1.8	157
64	Germline Mutation of von Hippel-Lindau (VHL) Gene 695 G>A (R161Q) in a Patient with a Peculiar Phenotype with Type 2C VHL Syndrome. Annals of the New York Academy of Sciences, 2006, 1073, 198-202.	1.8	5
65	Human Thyroid Autoantigens and Proteins ofYersiniaandBorreliaShare Amino Acid Sequence Homology That Includes Binding Motifs to HLA-DR Molecules and T-Cell Receptor. Thyroid, 2006, 16, 225-236.	2.4	43
66	Homologies Between Proteins of Borrelia burgdorferi and Thyroid Autoantigens. Thyroid, 2004, 14, 964-966.	2.4	49